Latest News

Media Release: “Relief” over Pharmac Decision to Fund First-Ever Treatment for Debilitating Form of Multiple Sclerosis

September 4, 2023 | Advocacy, Media, Progressive, Treatments

A seven year battle on behalf of hundreds of people living with the most debilitating form of Multiple Sclerosis has been won – with Pharmac agreeing to fund Aotearoa New Zealand’s first ever treatment for the disease variant  from October […]


2023 Election – Carers Alliance Briefing

August 14, 2023 | Advocacy, Carer, Petition

Carers NZ have published their Election Briefing asking Politicians and their parties how they will care for NZ’s one million plus family, whānau, and aiga carers. Download a copy here: Carers Election Briefing 2023 Final


‘Exhaustion and dread’ : Desperate carer calls for change

June 26, 2023 | Advocacy, Carer, Carers, Life with MS, Media, Petition, Progressive, Uncategorised

Speaking in support of the Carers Alliance petition, Maxine Hall, a carer for her husband with Multiple Sclerosis, speaks of her struggles and hopes that this campaign will at least raise awareness. View original article on Otago Daily Times: https://www.odt.co.nz/news/dunedin/exhaustion-and-dread-desperate-carer-calls-change […]


Media Release: Nationwide petition launched to fight “shocking” lack of fair support for carers

June 23, 2023 | Advocacy, Carer, Carers, Media, Petition

Media Release: Friday 5th June 2023 A powerful Alliance representing 56 national not-for-profits is demanding the Government stop “dragging its feet” to provide long overdue recognition and basic rights for the estimated one million largely unpaid New Zealanders struggling to […]


Major announcement: Pharmac Initiates Consultation to fund Ocrelizumab for Primary Progressive MS.

June 22, 2023 | Advocacy, Funding, Media, Progressive

Multiple Sclerosis New Zealand (MSNZ) is delighted to share that Pharmac have commenced consultation to fund Ocrelizumab for Primary Progressive MS. Currently, those with PPMS have no access to any disease modifying therapies. Ocrelizumab has been proven in trials to […]